178 related articles for article (PubMed ID: 3681368)
1. Mycosis fungoides: management with topical nitrogen mustard.
Hoppe RT; Abel EA; Deneau DG; Price NM
J Clin Oncol; 1987 Nov; 5(11):1796-803. PubMed ID: 3681368
[TBL] [Abstract][Full Text] [Related]
2. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides.
Chinn DM; Chow S; Kim YH; Hoppe RT
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):951-8. PubMed ID: 10192339
[TBL] [Abstract][Full Text] [Related]
3. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH; Martinez G; Varghese A; Hoppe RT
Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
[TBL] [Abstract][Full Text] [Related]
4. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis.
Lindahl LM; Fenger-Gron M; Iversen L
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):163-8. PubMed ID: 22229501
[TBL] [Abstract][Full Text] [Related]
5. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides in young patients: clinical characteristics and outcome.
Crowley JJ; Nikko A; Varghese A; Hoppe RT; Kim YH
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):696-701. PubMed ID: 9591813
[TBL] [Abstract][Full Text] [Related]
7. Management with topical nitrogen mustard in mycosis fungoides.
Kim YH
Dermatol Ther; 2003; 16(4):288-98. PubMed ID: 14686971
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
9. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides.
Navi D; Riaz N; Levin YS; Sullivan NC; Kim YH; Hoppe RT
Arch Dermatol; 2011 May; 147(5):561-7. PubMed ID: 21576575
[TBL] [Abstract][Full Text] [Related]
10. Topical nitrogen mustard in early mycosis fungoides. A 12-year experience.
Zachariae H; Thestrup-Pedersen K; Søgaard H
Acta Derm Venereol; 1985; 65(1):53-8. PubMed ID: 2578706
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
12. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Talpur R; Venkatarajan S; Duvic M
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
[TBL] [Abstract][Full Text] [Related]
13. Topical nitrogen mustard in mycosis fungoides.
Zachariae H
Int J Clin Pharmacol Res; 1985; 5(3):193-8. PubMed ID: 4018954
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides plaque stage treated with topical nitrogen mustard with and without attempts at tolerance induction: report from the Scandinavian mycosis fungoides study group.
Molin L; Thomsen K; Volden G
Acta Derm Venereol; 1979; 59(1):64-8. PubMed ID: 84470
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
16. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
[TBL] [Abstract][Full Text] [Related]
17. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
Delfau-Larue MH; Dalac S; Lepage E; Petrella T; Wechsler J; Farcet JP; Bagot M
Blood; 1998 Nov; 92(9):3376-80. PubMed ID: 9787176
[TBL] [Abstract][Full Text] [Related]
19. Response of mycosis fungoides to topical chemotherapy with mechlorethamine.
Ramsay DL; Parnes RE; Dubin N
Arch Dermatol; 1984 Dec; 120(12):1585-90. PubMed ID: 6508330
[TBL] [Abstract][Full Text] [Related]
20. Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate-term results.
Vonderheid EC; Van Scott EJ; Johnson WC; Grekin DA; Asbell SO
Arch Dermatol; 1977 Apr; 113(4):454-62. PubMed ID: 848974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
